STZ
58
3
EW
32
3
LNC
45
-4
DFS
67
-3
AMAT
43
-5
FDX
54
14
BAX
27
-2
SLB
56
-3
SRE
66
-3
NWSA
71
-2
EMC
53
-3
DRI
56
2
BA
45
-3
CMI
67
4
CF
53
2
HPE
70
2
FLS
76
-2
INTC
49
16
XRX
34
-3
PM
58
2
STZ
58
3
EW
32
3
LNC
45
-4
DFS
67
-3
AMAT
43
-5
FDX
54
14
BAX
27
-2
SLB
56
-3
SRE
66
-3
NWSA
71
-2
EMC
53
-3
DRI
56
2
BA
45
-3
CMI
67
4
CF
53
2
HPE
70
2
FLS
76
-2
INTC
49
16
XRX
34
-3
PM
58
2
Financhill
Back

Pliant Therapeutics 10K Form

Sell
45

PLRX
Pliant Therapeutics

Last Price:
12.85
Seasonality Move:
15.67%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLRX News And Ratings

See the #1 stock for the next 7 days that we like better than PLRX

PLRX Financial Statistics

Sales & Book Value

Annual Sales: $1.58M
Cash Flow: $-33.17M
Price / Cash Flow: 0
Annual Sales: $5.68
Price / Book: 2.43

Profitability

EPS (TTM): -3.34000
Net Income (TTM): $-201.68M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Pliant Therapeutics Earnings Forecast

Key Pliant Therapeutics Financial Ratios

  • The Research & Development expenses have been 8,088.42% of Revenue.
  • The Interest Expense is -0.79% of Operating Income.
  • The Net Earning history of PLRX is -10,211.14% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Pliant Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PLRX
CUSIP: 729139
Website: pliantrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PLRX Technical Analysis vs Fundamental Analysis

Sell
45
Pliant Therapeutics (PLRX) is a Sell

Is Pliant Therapeutics a Buy or a Sell?